CORTERIA PHARMACEUTICALS

Inventiva Secures €348 Million to Advance Phase 3 MASH Study of Lanifibranor

7 months ago

• Inventiva has secured €94.1 million in equity financing, part of a larger €348 million transaction, to advance its Phase 3 NATiV3 clinical trial for MASH. • The NATiV3 study is evaluating lanifibranor in over 1,100 patients with noncirrhotic MASH, with enrollment completion projected in the first half of 2025. • The financing includes up to $30 million in milestone payments from CTTQ and will support the MASH program, marketing approval filings, and potential commercialization of lanifibranor. • Mark Pruzanski, MD, has been appointed as Chairman of the Board, and Srinivas Akkaraju, MD, PhD, as a director, pending shareholder approval.